Trident Lifeline Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹47.1cr (+50% YoY), EBITDA ₹11.3cr (+65%), PAT ₹6.6cr (+30%). Capacity utilisation 46%. Parenterals facility pending commissioning.
- Call
- Guides 200% growth
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
3 announcements with these filters
Q2 FY27 consolidated revenue ₹47.1cr (+50% YoY), EBITDA ₹11.3cr (+65%), PAT ₹6.6cr (+30%). Capacity utilisation 46%. Parenterals facility pending commissioning.
Trident Lifeline (TLL) achieved ₹129 Cr consolidated revenue in FY26, a 48% increase. Strategy centers on a demand-led manufacturing model and aggressive global registration expansion.
Trident Lifeline achieved record FY26 revenue exceeding ₹100 crore with a 49% standalone revenue growth. The company maintains a hybrid manufacturing model focused on pharmaceutical formulation exports to emerging markets.